AB134. SOH26AB_0429b. Oncological outcomes of sentinel lymph node biopsy versus targeted axillary dissection in node-positive breast cancer patients after neoadjuvant chemotherapy: a systematic review and meta-analysis

Increasing evidence supports the oncologic safety of de-escalating axillary surgery after neoadjuvant chemotherapy (NAC). For patients with initially clinically node-positive (cN+) breast cancer whose axilla is down-staged after NAC (ycN0), sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) are acceptable approaches, but controversy remains regarding the optimal technique. The aim was to assess the oncological and survival outcomes of SLNB versus TAD for cN+ patients who convert to ycN0 after NAC.